Zai Lab (ZLAB) said late Thursday it has struck a licensing agreement to use MediLink Therapeutics' Tmalin antibody-drug conjugate platform for the development of its ZL-6201 investigational drug.
Financial terms were not disclosed.
Zai Lab said the partnership will expand its oncology pipeline with another drug targeting multiple solid tumors.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.